Diabetes Research and Clinical Practice
Volume 66, Issue 1 , Pages 49-56 , October 2004

Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine

  • Satish K. Garg

      Affiliations

    • Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    • Department of Pediatrics, University of Colorado Health Sciences Center, Denver, CO, USA
    • Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Campus Box B-140, Denver, CO 80262, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-303-315-6396; fax: +1-303-315-4124.
    • ,
  • Peter A. Gottlieb

      Affiliations

    • Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    • Department of Pediatrics, University of Colorado Health Sciences Center, Denver, CO, USA
    • Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Campus Box B-140, Denver, CO 80262, USA
    • ,
  • Mary E. Hisatomi

      Affiliations

    • Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Campus Box B-140, Denver, CO 80262, USA
    • ,
  • Anna D’Souza

      Affiliations

    • West Virginia University, P.O. Box 6201, Morgantown, WV 26506, USA
    • ,
  • Andrew J. Walker

      Affiliations

    • Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Campus Box B-140, Denver, CO 80262, USA
    • ,
  • Kenneth E. Izuora

      Affiliations

    • Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Campus Box B-140, Denver, CO 80262, USA
    • ,
  • H.Peter Chase

      Affiliations

    • Department of Pediatrics, University of Colorado Health Sciences Center, Denver, CO, USA
    • Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Campus Box B-140, Denver, CO 80262, USA

Received 24 July 2003 ,Revised 8 December 2003 ,Accepted 6 February 2004.

References 

  1. Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependant diabetes mellitus. N. Engl. J. Med. 329 (1993) 977–986.
  2. UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352 (1998) 837–853.
  3. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective six year study. Diab. Res. Clin. Pract. 1995;28:103–117
  4. Garg SK, Carmain JA, Braddy KC, Anderson JH, Vignati L, Jennings MK, et al. Pre-meal insulin analogue insulin Lispro vs. Human R insulin treatment in young subjects with type 1 diabetes. Diab. Med. 1996;13:47–52
  5. Heller SR, Amiel SA, Mansell P. Effect of the fast-acting insulin lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. UK Lispro Study Group. Diab. Care. 1999;10:1607–1611
  6. Chase HP, Lockspeiser T, Peery B, Shephard M, MacKenzie T, Anderson J, et al. The impact of the diabetes control and complications trial and humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes. Diab. Care. 2001;24:430–434
  7. Anderson JH, Brunelle RL, Koivisto VA, Pfutzner A, Trautmann ME, Vignati L, et al. Reduction of postprandial hyerglycemia and frequency of hyperglycemia in IDDM patients on insulin-analog treatment. Multicenter insulin lispro study group. Diabetes. 1997;2:265–270
  8. Bolli GB. Clinical strategies for controlling peaks and valleys: type 1 diabetes. Int. J. Clin. Pract. Suppl. 2002;129:65–74
  9. Ratner RE, Hirsh IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine (HOE901) in intensive insulin therapy for type 1 diabetes. Diab. Care. 2000;23:639–643
  10. Owens DR, Griffiths S. Insulin glargine (Lantus). Int. J. Clin. Pract. 2002;6:460–466
  11. Garg S, Gerard L, Pennington M, Mecca T, Taylor L, Chase P, et al. Efficacy of the new long acting insulin analog (HOE901) on fasting glucose values in IDDM. Diabetes. 1998;47:359
  12. Murphy NP, Keane SM, Ong KK, Ford-Adams M, Edge JA, Acerini CL, et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diab. Care. 2003;26:799–804
  13. Home PD, Ashwell SG. An overview of insulin glargine. Diabtes/Metabolism. 2002;18:S3
  14. Scholtz HE, Van Niekerk N, Meyer BH, Rosenkranz B. An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE 901 compared to NPH and Ultralente human insulins using the euglycaemic clamp technique. Diabetologia. 1999;42(Suppl. 1):A234
  15. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Viincenzo A, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and Ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;12:2142–2148
  16. D.L. Streiner, G.R. Norman, Biostatistics: the Bare Essentials, second ed., B.C. Decker Inc., Hamilton, London, 2000.
  17. B.G. Tabachnick, L.S. Fidell, Using Multivariate Statistics, fourth ed., Allyn & Bacon, 2000.
  18. S.B. Green, N.J. Salkind, Using SPSS for Windows and Macintosh: Analyzing and Understanding Data, third ed., Prentice-Hall, New Jersey, 2003.
  19. Hamann A, Matthaei S, Rosak C. The HOE901/4007 study group: once daily insulin glargine is effective and safe regardless of whether injected before breakfast or dinner, or at bedtime. Diabetes. 2002;51(Suppl. 2):A53
  20. Chase HP, Dixon B, Pearson J, Fiallo-Scharer R, Walravens P, Klingensmith G, et al. Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine hagedorn insulin. J. Pediatr. 2003;143:737–740
  21. Fritsche A, Matthias AS, Haring H. Improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes with morning administration of insulin glargine compared with NPH insulin. Diabetes. 2002;51(Suppl. 2):A54
  22. Vague P, Elte JWF, Selam J, Haahr H, Skeie S, Kristensen A, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH on a basal-bolus regimen with premeal insulin aspart. Diab. Care. 2003;26:590–596

PII: S0168-8227(04)00052-X

doi: 10.1016/j.diabres.2004.02.008

Diabetes Research and Clinical Practice
Volume 66, Issue 1 , Pages 49-56 , October 2004

Article Tools

* Image Usage & Resolution